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A B S T R A C T
Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn’s disease (CD), is an uncon-
trolled chronic inflammation of the gastrointestinal tract caused by an interaction of diverse genes and environmental
factors. There is growing evidence that cytokine production plays an important role in IBD. One of the key roles in signal-
ing pathway in development of IBD is performed by interleukin 6 (IL-6), although molecular mechanism of this pathway
is not yet fully understood. In order to assess the clinical relevance of IL-6 serum concentration in patients with CD and
UC we performed cross-sectional, case-control study of IL-6 levels in patients’ and healthy blood donors’ sera. A total of
100 CD and UC patients and 71 healthy blood donors were investigated. Clinical activity of CD and UC was evaluated
using the Crohn’s disease activity index and Truelove-Witt’s criteria, respectively. Quantitative assessment of serum IL-6
was performed with solid-phase, enzyme-labeled, chemiluminescent sequential immunometric assay. Our results indi-
cate that serum IL-6 is a clinically relevant parameter for CD and UC that strongly correlates with inflammatory activity
of disease. We confirmed and extended the role of cytokine production patterns for IBD presentation in Croatian popula-
tion.
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Introduction
Inflammatory bowel disease (IBD) is clinically and
histopathologically categorized into two basic subgroups
– Crohn’s disease (CD) and ulcerative colitis (UC). Both
are characterized by chronic relapsing bowel inflamma-
tion that responds to anti-inflammatory drugs such as
glucocorticoides and immunosupresives1. Continuous in-
flammation of the large intestine affecting both the colo-
nic mucosa and submucosa is characteristic only for UC
in contrast to CD which manifests itself most frequently
in distal ileum and colon2. IBD has been conceived of as
multifactorial disorder caused by an interplay between
environmental factors and multiple predisposing gene
variants, such as nucleotide oligomerization domain 2/Cas-
pase activation recruitment domains 15 (NOD2/CARD15)
polymorphisms, signal transducer and activator of tran-
scription-6 (STAT6), INFy, metalloproteinase (MMP18),
Vitamin D receptor (VDR) Th17 and b7 integrin family
members3–6. In addition, several other pathologically rel-
evant pathways have been recently identified in both dis-
orders including, but not restricted to immunity defects,
autophagy, epithelial barrier permeability defects and
loss of detoxification of intestinal drugs.
IBD is characterized by a predominantly T helper
(Th) 1 cellular profile, involving the up-regulation of
cytokines such as IL-6, IL-8, IL-1b and tumor necrosis
factor (TNF) a7,8. Among these, IL-6 is a pleiotropic
cytokine that functions in both innate and adaptive im-
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mune process and has a role in multitude of immune and
non-immune system reactions9. IL-6 production is gener-
ally correlated with cell activation and is normally kept
in control by glucocorticoids, catacholamines and second-
ary sex steroids10. Disruption of IL-6 regulation has been
related to several immune-mediated inflammatory dis-
eases such as rheumatoid arthritis, systemic juvenile
idiophatic arthritis, Castleman disease, various types of
cancer and IBD11. IL-6 plays a key role in acute phase re-
sponse which leads to STAT3-dependent changes in con-
centrations of plasma proteins such as C-reactive pro-
tein, serum amyloid A, haptoglobin, fibrinogen, albumin
and transferin12,13. IL-6 stimulates the proliferation of
mature T cells, differentiation of cytotoxic T cells and B
cells, activates the hypothalamic-pituitary-adrenal axis
by releasing adrenocorticotropic hormone14. Although
IL-6 is mostly regarded as proinflammatory cytokine it
also has many anti-inflammatory activities15,16. In order
to induce signal transduction, IL-6 first forms a complex
with IL-6 receptor (IL-6R) and afterwards associates
with gp130 whose cytoplasmic portion is sufficient to ac-
tivate Janus kinase (JAK) and STAT signal cascade. Con-
trary to membrane-bound IL-6R (mbIL-6R) gp130 is
ubiquitously expressed17–19. However, IL-6 exerts its bio-
logical function not only by association with mbIL-6R
but by forming a complex with the soluble IL-6R (sIL-6R)
and afterwards binds to gp13020.
Understanding cytokine production patterns in IBD
may be critical to understanding IBD pathogenesis21.
The aim of the present descriptive study is to provide in-
sight into pathological roles of IL-6 in IBD, and to inves-




The study population consisted of 100 (32 CD, 68 UC)
adult patients (52 males, median age 43, range 20–79
yrs) with IBD diagnosed at the Internal Clinic, Depart-
ment of Urgent and Intervention Gastroenterology, Uni-
versity Hospital Centre Osijek and at Zagreb University
Hospital Centre (Table 1). Seventy-one adult, otherwise
healthy blood donors with no clinical signs or family his-
tory of autoimmune diseases or malignancy were re-
cruited as controls. The median follow-up time for pa-
tients was 6 (interquartile range 3–12) years. Patients’
age, sex and relevant clinical and biochemical data were
extracted frommedical records. IBD diagnosis was estab-
lished on the basis of endoscopy findings, pathohysto-
logical and radiological criteria. Subjects with infective
and nonspecific colitis, multiple sclerosis, confirmed au-
toimmune or malignant diseases were excluded from the
study. There were 21 patients under treatment with
corticosteroids (8 CD and 13 UC patients). They received
either methylprednisolone (median dose 16, range 8–40
mg; N=9) or prednisone (median dose 17.5, range 5–40
mg, N=12). The following laboratory parameters were
assessed: erythrocyte sedimentation rate (ESR), white
blood cell count (WCC), C reactive protein levels (CRP),
serum albumin (ALB), alanin aminotransferasis (AST),
aspartate transaminase (ALT), and creatinine (CREAT).
Serology for IL-6 was conducted at Clinical Department
of Nuclear Medicine and Radiation Protection, Clinical
Hospital Centre Osijek, Croatia. Seventy-one healthy
blood donors were also investigated for IL-6 serum level.
Prior approval of the institutional ethical committee, as
well as patients’ and healthy blood donors’ informed con-
sent was obtained.
Biochemical measurements
Tests were performed on Siemens Immulite 1000 in
incubation cycles of 2x30 minutes according to company
protocol. Immulite IL-6 (Siemens Healthcare Diagnos-
tics, Llanberis, Gwynedd, United Kingdom) is a solid-
-phase, enzyme labeled, chemiluminescent sequential
immunometric assay. Specimens were collected by veni-
puncture in blood collection vacutainers without clot-
-promoting additives (BD Vacutainers Systems, Belliver
Industrial Estate, Plymouth, UK). To prevent erroneous
results due to the presence of fibrin, complete clot forma-
tion had taken place prior to centrifugation of samples.
Centrifugation step was performed in Hettich rotina 380
R centrifuge 15 min at 3,000 rpm. Serum samples were
aliquotted and stored at –20°C before analysis within one
hour of venipunction. Immulite IL-6 kit containing one
bead coated with a monoclonal murine anti-IL-6 anti-
body, two IL-6 reagent wedges. First contains 7.5 ml of a
protein/buffer matrix and second of 7.5 ml alkaline phos-
phatase (bovine calf intestine) conjugated to polyclonal
sheep anti-IL-6 antibody in buffer and IL-6 low and high
adjustors of lyophilized IL-6 in a protein buffer matrix.
Calibration range is up to 1,000 pg/ml and high-dose
hook effect is none up to 60,000 pg/ml. IL-6 assay was
calibrated due to low and high adjustors both reconsti-
tuted with 3 ml distilled water and mixed by swirling un-
til lyophilized material was fully dissolved. Both were
run in tetraplicates. For positive test verification as an
aid in monitoring performance of assays two controls
contained different concentrations of selected lyophilized
cytokines in a human serum matrix were used. Both
were reconstituted with 5 ml distilled water inside of 30
minutes prior to use and mixed until lyophilized material
was fully dissolved. The controls were assayed in the
same manner as patient samples, in the context of an in-
ternal quality follow-up. The result for control one was
97.3 pg/ml (expected range was from 74 to 104 pg/ml).
The result for control two was 422 pg/ml (expected range
varying from 365 to 543 pg/ml).
Statistical analysis
Data are presented as medians (ranges) and counts
(percentages) depending on the scale of the measure.
Mann-Whitney and Kruskal-Wallis tests with Schaich-
-Hamerle post hoc procedures were used for group com-
parisons. Relations between variables were tested by
Spearman rank test. All statistical analyses were per-
formed with Statistical Package for Social Sciences, ver-
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sion 17.0 SPSS Inc., Chicago, IL, USA. Two-sided p-val-
ues <0.05 were considered significant.
Results
Patients’ characteristics and biochemical data are pre-
sented in Tables 1 and 2, respectively.
The majority of patients (N=79) were treated with
mesalamine (median dose 2,500 mg, range 1,000–4,000
mg). IL-6 serum levels were separately assessed in CD
(CDAI median: 109), UC (MTLWSI median: 6) patients
and healthy controls (Table 3). In both CD patients and
UC patients concentrations of IL-6 were significantly
higher (c2=50.64, df=2, p<0.001, Kruskal-Wallis test)
when compared to healthy blood donors (Table 3). In ei-
ther CD or UC patients there were no significant differ-
ences in concentrations of IL-6 between patients under
corticosteroid treatment and patients receiving no cor-
ticosteroid therapy (c2=5.44, df=3, p=0.142, Kruskal-
-Wallis test).
The relationship between IL-6, clinical and biochemi-
cal data was investigated using Spearman rank order
correlation coefficient in CD and UC patients separately.
In both CD and UC patients, a strong positive correlation
was seen between ESR and IL-6 levels (r=0.54, p<0.01
and r=0.67, p<0.01, respectively), and CRP and IL-6 lev-
els (r=0.68, p<0.01 and r=0.78, p<0.01, respectively). In
both patients’ groups a positive correlation between WCC
and IL-6 levels was seen, more pronounced in UC pa-
tients (r=0.53 vs. 0.42, p<0.01). In both groups, an in-
verse correlation between ALB and IL-6 levels was found
(CD patients, r=–0.42, p<0.05; UC patients, r=0.59,
p<0.01). In CD patients, CDAI correlated positively with
IL-6 (r=0.48, p<0.01). Similarly, a highly significant pos-
itive correlation was found between MTLWSI and serum
IL-6 (r=0.66, p<0.01) (Table 4). In UC patients, addi-
tional inverse correlations were found between HGB and
IL-6 (r=–0.43, p<0.01), HCT and IL-6 (r=–0.33, p<0.05),
and CREAT and IL-6 (r=–0.28, p<0.05).
Mann-Whitney test was conducted to compare the
IL-6 serum level for CD patients with previous intestinal
resections with other CD patients. There was no statisti-
cally significant difference between the two subgroups of
CD patients (p=0.313).
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TABLE 1
DEMOGRAPHIC CHARACTERISTICS OF STUDY POPULATION OF








BIOCHEMICAL DATA OF CD (N=32) AND UC PATIENTS (N=68)
Parameter
CD patients (N=32) UC patients (N=68)
Median Range Median Range
Crohn’s disease activity index 109 30–469 – –
Modified Truelove & Witts Severity Index – – 6 0–17
Erythrocyte Sedimentation Rate 18 1–68 20 1–145
White Blood Cell Count 8.2 4.19–16.1 8.6 3.4–24.5
Erythrocytes 4.4 3.43–5.59 4.53 2.22–5.98
Hemoglobin 125 65–163 127 77–181
Hematocrit 0–36 0.31–0.47 0.38 0.21–0.51
Alanin Aminotransferasis 18 11–37 19 9–135
Aspartate Transaminase 15 2–54 19.5 6–167
Serum Albumin 40 26.4–51.1 38 19.9–51.5
Creatinine 74 42–100 76.5 37–135
C Reactive Protein 7.7 0.2–187.5 6.85 0.2–421
TABLE 3
IL-6 LEVELS IN CD AND UC PATIENTS AND HEALTHY CONTROLS
CD patients (N=32) UC patients (N=68) Healthy controls (N=71)
Median Range Median Range Median Range
Interleukin 6 (pg/ml) 3.25* 1.99–13.7 2.67** 1.99–118 1.99 1.99–4.03
* – CD vs. healthy controls, p<0.001, Schaich-Hamerle post-hoc test, ** – UC vs. healthy controls, p<0.001, Schaich-Hamerle post-hoc test
Finally, Mann-Whitney test was conducted to com-
pare the IL-6 serum level for inactive (CDAI<150) CD
patients (mediaN=1.99, range=1.99–9.36, N=17) with
healthy blood donors (mediaN=1.99, range=1.99–4.03,
N=71). There was a statistically significant difference
between the two groups of participants (z=–3.896, p=
0.000).
Discussion and Conclusion
In the present study we explored the role of IL-6 in
IBD and investigated whether serum IL-6 level is a rep-
resentative parameter of CD and UC activity. Examined
by single point measurement, serum IL-6 level was found
to significantly correlate with severity and extent of in-
flammatory bowel disease. Similarly it has been shown
that serum IL-6 level was substantially elevated in pa-
tients with IBD22 and positively correlated with inflam-
matory activity of disease23. In addition, increased serum
levels of sIL-6R and IL-6/sIL-6R complexes were re-
ported, suggesting an active IL-6 trans-signaling mecha-
nism operating through membrane-bound gp130 in
IBD24–26. This is crucial in mechanism of IL-6 activity be-
cause only small fractions of cells express mbIL-6R,
mainly hepatocytes, macrophages, neutrophils and some
lymphocytes17,27. We have shown in our study that serum
IL-6 levels in patients with active CD (CDAI>150) were
significantly higher when compared to patients with in-
active CD (CDAI<150, and that serum IL-6 levels in pa-
tients with inactive CD were significantly higher than
those in healthy blood donors. CRP and ESR mirrored
IL-6 levels, possibly reflecting the existence of remaining
lesions, activation of the mucosal immune system or ab-
normal intestinal permeability, all of which can stimulate
IL-6 synthesis in inactive CD patients, but it could also
be attributed to the existence of subclinical, yet relevant
residual inflammatory activity of the disease. These bio-
logical abnormalities have also been reported to be asso-
ciated with an increased risk of relapse assessed over a
short to medium period of time, usually one year28–30. In-
terestingly, in contrast to our study, some previous stud-
ies could not unequivocally disclose a relationship be-
tween serum IL-6 levels and scores of clinical activity
which has been attributed to the effect of steroid medica-
tion which inactivates proinflammatory transcription
factors and reduces half-lives and utility of cytokine
mRNA thus inhibiting IL-6 synthesis21,31.
CRP value was elevated in both CD and UC groups
and positively correlated with IL-6 serum value. IL-6 is a
principal cytokine that induces the production of acute
phase reactants like the CRP. CRP is responsible for
IL-6R shedding thus enhancing the effects of IL-632. Fur-
thermore, it has been reported that serum concentra-
tions of various acute phase proteins anticipate clinical
relapses, but only the combination of several laboratory
tests provides a reliable predictive index14,33.
Although a comparison of CD patients with intestinal
resection with CD patients who did not have previous in-
testinal resections did not yield statistically significant
differences, we believe that the observed lower IL-6 se-
rum levels in patients with intestinal resection might
have potential implications. Namely, substantial reduc-
tion of inflammatory tissue is performed by intestinal re-
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TABLE 4




N p r N p r
Crohn’s disease activity index 28 0.481 0.009** – –
Disease duration 31 0.188 0.311 68 0.027 0.824
Age 32 0.115 0.532 68 0.019 0.877
Duration 31 –0.081 0.663 68 –0.096 0.437
Modified Truelove & Witts Severity Index – – 67 0.669 0.000**
Erythrocyte Sedimentation Rate 30 0.544 0.001** 60 0.671 0.000**
White Blood Cell Count 30 0.451 0.012* 65 0.536 0.000**
Erythrocytes 30 –0.211 0.261 62 –0.202 0.114
Hemoglobin 30 –0.324 0.081 61 –0.436 0.000**
Hematocrit 23 –0.139 0.525 46 –0.335 0.023*
Alanin Aminotransferasis 29 –0.037 0.848 60 –0.221 0.089
Aspartate Transaminase 29 –0.117 0.546 60 –0.083 0.526
Serum Albumin 27 –0.420 0.028* 53 –0.591 0.000**
Creatine 28 0.078 0.691 60 –0.281 0.029*
C Reacitve Protein 30 0.682 0.000** 64 0.787 0.000**
Interleukin 23 32 0.171 0.349 67 –0.039 0.753
* – p<0.05, ** – p<0.001
section and thus inflammatory stimuli are diminished
which could lead to decrease of intestinal IL-6 release to
systemic circulation. Lack of statistical significance in
the present study concerning intestinal resection may be
attributed to the small sample size, although some differ-
ences may also be attributed to varying therapeutic mo-
dalities.
Measurement of serum IL-6 levels might be a useful
tool to stratify patients with high risk of relapse. How-
ever, the present study is limited by a lack of longitudinal
measurement of serum IL-6 in steroid induced remission
which we believe would yield a better insight into IL-6
dynamics and usefulness of IL-6 serum value as relapse
predictive factor. This will be further explored in our fu-
ture research. Our results demonstrated that serum IL-6
reflects inflammatory activity in patients with CD and
UC, and overall seems to be a good predictor of IBD activ-
ity. Given a prominent role of IL-6 signaling in both CD
and UC pathogenesis, IL-6 can be considered as an im-
portant target for cytokine specific therapies.
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VA@NOST INTERLEUKINA 6 U PATOGENEZI UPALNIH BOLESTI CRIJEVA
S A @ E T A K
Upalne bolesti crijeva (engl. inflammatory bowel disease – IBD) koje obuhva}aju ulcerozni kolitis i Crohnovu bolest
su nekontrolirane kroni~ne upale gastrointestinalnog trakta uzrokovane interakcijom razli~itih genskih faktora i fak-
tora okoli{a. Sve je vi{e dokaza da produkcija citokina ima va`nu ulogu u upalnim bolestima crijeva. Jednu od klju~nih
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uloga u razvoju upalnih bolesti crijeva ima interleukin 6 (IL-6), iako molekularni mehanizmi djelovanja jo{ nisu u
potpunosti obja{njeni. Kako bismo procijenili klini~ku va`nost serumske koncentracije IL-6 u pacijenata oboljelih od
ulceroznog kolitisa i Crohnove bolest, proveli smo ispitivanje razine IL-6 u serumima oboljelih i zdravih donatora krvi.
Istra`ivanje je obuhvatilo ukupno 100 pacijenata oboljelih od Crohnove bolesti i ulceroznog kolitisa i 71 zdravih dona-
tora krvi. Klini~ka aktivnost Crohnove bolest mjerena je pomo}u indeksa aktivnosti Crohnove bolesti, a ulceroznog
kolitisa pomo}u Truelove-Wittsovih kriterija. Kvantitativno odre|ivanje serumske koncentracije IL-6 u~injeno je kemi-
luminescentnim sekvencijalnim imunometri~kim testom. Rezultati upu}uju na zaklju~ak da je serumski IL-6 klini~ki
relevantan parametar za obje bolesti koji sna`no korelira s upalnom aktivno{}u bolesti. Potvrdili smo i pro{irili ulogu i
zna~aj sinteze citokina u upalnim bolestima crijeva u hrvatskoj populaciji.
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